Ziopharm Oncology
NASDAQ: TCRTBoston, US · Delaware corporation · 1 known investors
Find your way into Ziopharm Oncology
329 people in our graph share verified history with the Ziopharm Oncology team — schools, employers, funds. One of them is your warm intro.
Dougunlockedknows Jonathan Lewis · together at Yale University (overlapped)
knows the team · via University of Cambridge
×6knows the team · via Yale University
×2knows the team · via University of the Witwatersrand
×2knows the team · via Memorial Sloan Kettering Cancer Center
Ziopharm Oncology is a preclinical-stage biopharmaceutical company developing orally administered small-molecule drugs for obesity and metabolic disorders, particularly fatty liver disease, using a non-hormonal mechanism distinct from existing hormone-based treatments. The company previously operated as an oncology-focused cell therapy developer but has transitioned its focus to metabolic disease.
Founders & leadership
KL
Kevin LafondExecutive
CB
Caesar BelbelExecutive
JL
Jonathan LewisinChief Executive Officer, Executive Chairman and Co-Founder2004–2015Jonathan Lewis is Executive Chairman of Stealth Mode Biotechs, where he focuses on development and investment initiatives in biotech, and serves as Chairman of Dugri, Inc., a company developing interaction protocols for first responder and military communities.
DC
Dale Curtis Hogue, Jr.Interim Chief Executive Officer and Director
Board
RK
Randal KirkBoard director
TM
Timothy McInerneyBoard director
MW
Michael WeiserBoard director
WF
Wyche FowlerBoard director
MB
Murray BrennanBoard director
JC
James CannonBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$352.1M disclosed across 5 rounds · 2015–2019
▶$19.5MraisedSep 2019 · 1 investors · BiotechnologyRule 506(b)
▶$19.5MraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sath ShuklaExecutive Officer
- Heidi HagenDirector
- Scott BraunsteinDirector
- Elan Z. EzicksonDirector
- Douglas W. PaganDirector
- Scott TarriffDirector
- Eleanor De GrootExecutive Officer
- Robert HadfieldExecutive Officer
- David M. MauneyExecutive Officer
- Kevin G. LafondExecutive Officer
- Laurence J.N. CooperExecutive Officer, Director
- Jill BuckExecutive Officer
- Offering amount
- $19.5M
- Amount sold
- $19.5M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$105.1MraisedAug 2019 · 5 investors · BiotechnologyRule 506(b)
▶$105.1MraisedAug 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laurence J.N. CooperExecutive Officer, Director
- Kevin G. LafondExecutive Officer
- Robert HadfieldExecutive Officer
- David M. MauneyExecutive Officer
- Jill BuckExecutive Officer
- Scott TarriffDirector
- Sath ShuklaExecutive Officer
- Heidi HagenDirector
- Scott BraunsteinDirector
- Elan Z. EzicksonDirector
- Douglas W. PaganDirector
- Eleanor De GrootExecutive Officer
- Offering amount
- $105.1M
- Amount sold
- $105.1M
- Sales commissions
- $1M
- Placement agents
- Raymond James & Associates, Inc.
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedNov 2018 · 7 investors · BiotechnologyRule 506(b)
▶$50MraisedNov 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas W. PaganDirector
- Robert HadfieldExecutive Officer
- Kevin G. LafondExecutive Officer
- Scott TarriffDirector
- Scott BraunsteinDirector
- David MauneyExecutive Officer
- Laurence J.N. CooperExecutive Officer, Director
- James A. CannonDirector
- Elan Z. EzicksonDirector
- Offering amount
- $107M
- Amount sold
- $50M
- Sales commissions
- $2.5M
- Placement agents
- Raymond James & Associates, Inc.
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$120MraisedJul 2016 · 1 investors · BiotechnologyRule 506(b)
▶$120MraisedJul 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laurence J.N. CooperExecutive Officer
- Scott TarriffDirector
- Kevin G. LafondExecutive Officer
- Wyche Fowler, Jr.Director
- Caesar BelbelExecutive Officer
- Michael WeiserDirector
- Randal J. KirkDirector
- James CannonDirector
- Francois LebelExecutive Officer
- Murray BrennanDirector
- Offering amount
- $120M
- Amount sold
- $120M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$57.5MraisedJan 2015 · 1 investors · BiotechnologyRule 506(b)
▶$57.5MraisedJan 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin LafondExecutive Officer
- Wyche FowlerDirector
- Murray BrennanDirector
- Randal KirkDirector
- Caesar BelbelExecutive Officer
- Timothy McInerneyDirector
- James CannonDirector
- Michael WeiserDirector
- Jonathan LewisExecutive Officer, Director
- Offering amount
- $57.5M
- Amount sold
- $57.5M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Ziopharm Oncology went on to found or lead other companies.
In the news
Frequently asked questions
- What does Ziopharm Oncology do?
- Ziopharm Oncology is a preclinical-stage biopharmaceutical company developing orally administered small-molecule drugs for obesity and metabolic disorders, particularly fatty liver disease, using a non-hormonal mechanism distinct from existing hormone-based treatments. The company previously operated as an oncology-focused cell therapy developer but has transitioned its focus to metabolic disease.
- Who are Ziopharm Oncology's investors?
- Ziopharm Oncology's investors include Cycad Group LLC.
- How much funding has Ziopharm Oncology raised?
- Ziopharm Oncology has disclosed $352.1M raised across 5 rounds.
- Where is Ziopharm Oncology headquartered?
- Ziopharm Oncology is headquartered in Boston, US.